Advertisement

The ASCO Post Newsreels help clinicians stay up to date on news in the world of clinical oncology and hematology. Newsreels feature leading authorities presenting high-impact clinical findings at major oncology meetings throughout the year.



Showing All Recent Newsreels Videos


Advertisement

2026 ASCO GU

Scott Tyldesley, MD, FRCPC, on Localized Prostate Cancer: External Beam vs Brachytherapy Boost RT

Anna Clare Wilkins, PhD, MRCP, MBBChir, on Localized Prostate Cancer: MMAI-Derived Biomarker

Enrique Gallardo, MD, on mCRPC: Enzalutamide With or Without Radium-223

Amar Kishan, MD, on Recurrent Prostate Cancer: Hormone Therapy and Postoperative Radiotherapy


2026 ASCO GI

Ghassan K. Abou-Alfa, MD, on a Novel First-Line Regimen for Unresectable HCC Under Study

Ghassan K. Abou-Alfa, MD, on Tremelimumab Rechallenge in Unresectable HCC: Safety Outcomes

Samuel J. Klempner, MD, on Advanced Gastric/GEJ Cancer: Zolbetuximab Plus mFOLFOX6 and Nivolumab

Elizabeth Smyth, MD, on FLOT Administration in the MATTERHORN Trial

Elena Elimova, MD, on HER2-Positive Gastroesophageal Cancer: Zanidatamab Plus Chemotherapy

Daniela Molena, MD, on Surgical Journey in the MATTERHORN Trial

Dina Ioffe, MD, on Disparities in HCC: Do They Affect Systemic Care?

Matthew Strickland, MD, on Locally Advanced Gastric/GEJ Cancer: Tislelizumab Plus Chemoradiotherapy

Stephen Lam Chan, MD, FRCP, MRCP, on HCC: Pembrolizumab After Resection or Local Ablation

Marcel Verheij, MD, PhD, on Resectable Gastric Cancer: Comparing Three Preoperative Regimens


SABCS 2025

Jame Abraham, MD, FACP, on a Novel Oral SERD for ER-Positive, HER2-Negative Early Breast Cancer

Jame Abraham, MD, FACP, on T-DXd in HER2-Positive Early Breast Cancer: Follow-up Data

Jame Abraham, MD, FACP, on HER2-Positive Metastatic Breast Cancer: Choosing a Regimen in Clinical Practice

Joseph A. Sparano, MD, on Multimodal AI Models for Predicting Breast Cancer Recurrence


ASH 2025

Jack Khouri, MD, on Multiple Myeloma: Burixafor and Propranolol With G-CSF Before Transplant

Aaron Logan, MD, PhD, on Relapsed/Refractory B-Cell ALL: Real-World Data on Brexucabtagene Autoleucel and Transplant

Jayastu Senapati, MBBS, on B-Cell ALL: Brexucabtagene Autoleucel as Consolidation Therapy

Valeria Santini, MD, on Imetelstat for Lower-Risk MDS: Long-Term Outcomes From the IMerge Trial

Ibrahim Aldoss, MD, on Older Adults With B-Cell ALL: CD19 CAR T-Cell Therapy

Anand Patel, MD, on Ph-Positive ALL: TKI Plus Inotuzumab Ozogamicin–Based Therapy

Othman Al-Sawaf, MD, PhD, on Previously Untreated CLL: Fixed-Duration vs Continuous Targeted Treatment

Amir Fathi, MD, on Newly Diagnosed AML: Azacitidine and Venetoclax vs Conventional Induction Chemotherapy

Krina Patel, MD, MSc, on Anitocabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

Benjamin Diamond, MD, on a Novel Quadruplet for Relapsed/Refractory Multiple Myeloma

Guillermo Garcia-Manero, MD, on MDS: Research Highlights From ASH 2025

Dory Abelman, PhD(c), HBHSc, on Newly Diagnosed Multiple Myeloma: Ultradeep Whole-Genome Sequencing of cfDNA

Aaron Gerds, MD, on Using an AI System to Identify Patients Eligible for a Polycythemia Vera Trial

Shahzad Raza, MD, on Relapsed/Refractory Multiple Myeloma: Novel Doublet in Patients With Extramedullary Disease

Karthik Ramasamy, MBBS, FRCP, FRCPath, PhD, on Ultra–High-Risk Multiple Myeloma: RADAR Trial in Newly Diagnosed Transplant-Eligible Patients

Alexander Lesokhin, MD: Can Patients With Relapsed/Refractory Multiple Myeloma Successfully Pause or Discontinue Elranatamab?

Brian Ball, MD, on Higher-Risk MDS: Bexmarilimab and Azacitidine

Jennifer Woyach, MD, on CLL/SLL: Pirtobrutinib vs Ibrutinib in Treatment-Naive and Relapsed/Refractory Disease

Jennifer Woyach, MD, on Relapsed/Refractory CLL: Next-Generation BTK Inhibitor

Amer Zeidan, MBBS, on Lower-Risk MDS: Treatment-Emergent Cytopenias and Clinical Response

Amer Zeidan, MBBS, on TP53-Mutated Higher-Risk MDS: Bexmarilimab Plus Azacitidine

Andrew Portuguese, MD, on Multiple Myeloma: Real-World Outcomes With Elranatamab

Nitin Jain, MD, on a Triplet Regimen for Richter Transformation

Mikkael Sekeres, MD, MS, on MDS and Exposure to Agent Orange


JADPRO Live 2025

JADPRO Live 2025: United in Care


ESMO Congress 2025

Emese Zsiros, MD, PhD, on Platinum-Resistant Recurrent Ovarian Cancer: Pembrolizumab Plus Weekly Paclitaxel

Andrew R. Clamp, MD, PhD, on High-Risk Ovarian Cancer: Weekly Dose-Dense and Every-3-Week Chemotherapy Plus Bevacizumab

Domenica Lorusso, MD, PhD, on Platinum-Resistant Ovarian Cancer: Relacorilant and Nab-Paclitaxel in Pretreated Patients


IASLC WCLC 2025

Jordi Remon, MD, PhD, on Aumolertinib Plus Chemotherapy in EGFR-Mutated NSCLC

John M. Varlotto, MD, on Concurrent and Consolidation Durvalumab for Unresectable Stage III NSCLC

Jonathan Spicer, MD, PhD, on Perioperative Immunotherapy for Resectable NSCLC: HRQoL Outcomes

Susan C. Scott, MD, on EGFR-Mutated NSCLC: Subcutaneous Amivantamab Plus Lazertinib

Alexander Drilon, MD, on ROS1 Fusion–Positive NSCLC: Efficacy of Zidesamtinib

Kelly G. Paulson, MD, PhD, on Extensive-Stage SCLC: Tarlatamab Plus Anti–PD-L1 as Maintenance Therapy

David Gerber, MD, on ALK-Positive NSCLC: Crizotinib vs Observation for Surgically Resected Early-Stage Disease

Gerrina Ruiter, MD, PhD, on Zongertinib in Patients With Previously Treated HER2-Mutant NSCLC and Baseline Brain Metastases

Patrick Goodley, MBBChir, MRCP: What Is the Optimal Upper Age Limit for Lung Cancer Screening?


SOHO 2025

Elias Jabbour, MD, on CAR T-Cell Therapy for Adult Patients With Relapsed/Refractory B-Cell ALL

Farhad Ravandi, MD, on AML: Highlights of Ongoing Research

Nirav N. Shah, MD, MSHP, on a BTK Degrader in Relapsed or Refractory CLL

Michael J. Mauro, MD, on the ENABLE Study in Heavily Pretreated Patients With CML

Naval G. Daver, MD, and Uma Borate, MBBS, Debate Lower-Intensity Regimens in AML

Nicholas J. Short, MD: Focus on TP53-Mutated ALL

Bijal Shah, MD, on CAR T-Cell Therapy in ALL


2025 ASCO Annual Meeting

William G. Wierda, MD, PhD, on Fixed-Duration Ibrutinib and Venetoclax in First-Line CLL

William G. Wierda, MD, PhD, on Lisocabtagene Maraleucel in Relapsed/Refractory CLL: TRANSCEND CLL 004 

Giuseppe Curigliano, MD, PhD, on Patient-Reported Outcomes From EMBER-3

Nicholas C. Turner, MD, PhD, on INAVO120: Final Overall Survival Analysis

Constantine Si Lun Tam, MD, FRACP, FRCPA, MBBS, on CLL/SLL: First-Line Zanubrutinib Monotherapy in Patients With del(17p)

Christopher M. Booth, MD, on a Structured Exercise Program for Patients With Colon Cancer

Andrew Kuykendall, MD, on Hepcidin Mimetic for Polycythemia Vera

Stuart J. Wong, MD, on Adjuvant Regimen in Resected HNSCC

Nicholas C. Turner, MD, PhD, on Treating Emergent ESR1 Mutations in Advanced Breast Cancer

Raffaele Califano, MD, on EGFR-Mutant Advanced NSCLC: MARIPOSA-2

Yelena Y. Janjigian, MD, on Gastric/GEJ Cancer: Immunotherapy Plus FLOT

Mazyar Shadman, MD, PhD, on Doublet for Treatment-Naive CLL/SLL

Heinz-Josef Lenz, MD, on MSI-H/dMMR Metastatic Colorectal Cancer: Expanded Analyses From CheckMate 8HW

Clifford A. Hudis, MD, FASCO, FACP, on ASCO Guidelines Assistant

Andrew J. Armstrong, MD, MS, on ARCHES: 5-Year Overall Survival Follow-up

David Allen Barbie, MD, on Clinical and Molecular Features of Participants in the ADRIATIC Trial

Mafalda Oliveira, MD, PhD, on How Does Hyperglycemia Affect Treatment of Advanced Breast Cancer?

Arelis Esther Martir-Negron, MD, on Prevalence of BRCA Variants in Hispanic Residents of South Florida

Sara M. Tolaney, MD, MPH, FASCO, on PD-L1–Positive Advanced TNBC: First-Line Doublet Comparison

Elena Elez, MD, PhD, on Updated Survival Data From the BREAKWATER Trial

Karen Eubanks Jackson on Receiving the 2025 ASCO Patient Advocate Award

Manmeet Singh Ahluwalia, MD, MBA, FASCO, on Liquid Biopsy in Glioblastoma

Sameek Roychowdhury, MD, PhD, on Telemedicine in Clinical Trials

Angela R. Bradbury, MD, on Genetic Testing Approach in Patients With Metastatic Cancers

David R. Spigel, MD, FASCO, on NSCLC Treatment Planning: Role of 14-Gene Molecular Assay

Stephen K.L. Chia, MD, FRCPC, on Advanced HER2-Negative and ER-Positive Breast Cancer: SERD and AKT Inhibitor

Alicia Latham, MD, MS, on Using ctDNA to Detect Endometrial Cancer

Frank A. Sinicrope, MD, on Adjuvant Treatment Strategies for Stage III dMMR Colon Cancer

Martin Reck, MD, PhD, on Postsurgical MRD, Genomic Mutations, and Outcomes in Resectable NSCLC: AEGEAN Trial

Asaf Maoz, MD, on Pancreatic Surveillance Eligibility Criteria

Asaf Maoz, MD, on Li-Fraumeni Syndrome: Multimodality Screening Program 

Rami Manochakian, MD, FASCO, on Tarlatamab vs Chemotherapy for Second-Line Treatment of SCLC: Expert Point of View

Alicia K. Morgans, MD, MPH, FASCO, on How Does Androgen Receptor Inhibition Affect Quality of Life?

Nicholas D. James, PhD, FRCP, MBBS, on Using AI to Identify Benefit From Prostate Cancer Therapy

Bjorn Henning Gronberg, MD, PhD, on SCLC: Adjuvant Immunotherapy After CRT

Jamie E. Chaft, MD, FASCO, on Resectable EGFR-Mutated NSCLC: NeoADAURA Results

Shahzad Raza, MD, on Relapsed or Refractory AL Amyloidosis: First U.S. Trial of CAR T-Cell Therapy

Nitin Jain, MD, on Front-Line Therapies for CLL: Research Highlights From ASCO 2025

Luis G. Paz-Ares, MD, PhD, on IMforte Trial in Extensive-Stage SCLC

Luis G. Paz-Ares, MD, PhD, on Extensive-Stage SCLC: Comparison of First-Line Regimens

Suneel Deepak Kamath, MD, on Disparities in NIH and Federal Funding Across Different Cancer Types

Praful Ravi, MBBChir, MRCP, on High-Risk Localized Prostate Cancer: Docetaxel With ADT and Radiotherapy

Eric Huttenlocher Bent, MD, PhD, on Oligometastatic Prostate Cancer: Intensified Hormonal Blockade

Neil M. Iyengar, MD, on Cancer Risk Reduction: Effects of Menopausal HRT and GLP-1 RAs

Hope S. Rugo, MD, FASCO, and Rebecca Alexandra Dent, MD, FASCO, on Breast Cancer Data Highlights: Sequencing of Endocrine Therapy

Violaine Randrian, MD, PhD, on Lynch Syndrome, Genetics, and Immunotherapy

Ruben A. Mesa, MD, on Essential Thrombocythemia: SURPASS-ET Trial

Gerhardt Attard, MD, PhD, on a Novel Regimen for Metastatic Castration-Sensitive Prostate Cancer With HRR Alterations

Erika Hamilton, MD, on ER-Positive HER2-Negative Advanced Breast Cancer: Vepdegestrant vs Fulvestrant

Advertisement

Advertisement




Mar
01
Today In Oncology
‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?
Medical Societies and More Respond to HHS RFI on AI Use in Clinical Care
Perioperative Enfortumab Vedotin Plus Pembrolizumab May Reduce Risk of Recurrence in Patients With Muscle-Invasive Bladder Cancer
SABCS 2025: Top Picks From a Breast Cancer Specialist
Intravesical Immunotherapy Shows Recurrence Control in BCG-Unresponsive Papillary-Only Non–Muscle-Invasive Bladder Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo